Tirzepatide 10MG

Product Specifications

• Compound: Tirzepatide (Dual GIP/GLP-1 Receptor Agonist)
• CAS Number: 2023788-19-2
• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight: 4813.45 g/mol
• Sequence: 39 amino acid linear peptide with C-20 fatty diacid modification
• Purity: 99.88% (HPLC-UV verified, this batch)
• Form: Lyophilized powder
• Quantity: 10mg per vial
• Third-Party Testing: Independent third-party laboratory, Batch-specific COA available

Mechanism of Action

Tirzepatide is a synthetic 39-amino acid peptide engineered as a dual agonist targeting both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. In-vitro receptor binding assays demonstrate that tirzepatide exhibits approximately 5-fold selectivity for the GIP receptor relative to GLP-1, distinguishing it from selective GLP-1 receptor agonists such as semaglutide. The peptide incorporates a C-20 fatty diacid moiety that facilitates albumin binding, extending its pharmacokinetic half-life in preclinical models.

Research Applications

Tirzepatide has been investigated across multiple preclinical research domains. In-vitro studies have demonstrated its effects on incretin signaling pathways, including cAMP accumulation in GIP and GLP-1 receptor-expressing cell lines. Binding assays confirm dual receptor engagement with distinct activation kinetics compared to mono-agonist compounds.

In animal models, tirzepatide research has examined its influence on pancreatic islet cell function, including glucose-dependent insulin secretion and glucagon suppression pathways. Rodent studies have investigated effects on central metabolic signaling, hepatic lipogenesis markers, adipose tissue remodeling, and energy expenditure pathways. Researchers have utilized tirzepatide as a tool compound for exploring the synergistic effects of simultaneous GIP and GLP-1 receptor activation versus single-receptor agonism.

Additional preclinical investigations have examined tirzepatide’s effects on inflammatory biomarkers (IL-6, TNF-alpha, CRP), lipid metabolism gene expression, mitochondrial biogenesis markers, and cardiovascular parameters in various tissue and animal models.

Key Research Literature

Published studies on tirzepatide and dual incretin agonism have appeared in journals including Nature Medicine, The Lancet, and the New England Journal of Medicine. Research areas include incretin receptor pharmacology, biased agonism at GIP/GLP-1 receptors, and comparative analyses with selective GLP-1 receptor agonists. For a detailed review of the research landscape, see our Tirzepatide Research Overview.

How Tirzepatide Compares to Other Research Peptides

Tirzepatide belongs to the incretin-targeting peptide family alongside semaglutide (selective GLP-1 agonist) and retatrutide (triple GIP/GLP-1/glucagon agonist). While semaglutide activates only the GLP-1 receptor, tirzepatide’s dual mechanism engages both GIP and GLP-1 pathways. Retatrutide adds a third target (glucagon receptor). For comparative research data, see our Peptide Comparison Guide and GLP-1 Incretin Pathway Research.

Storage and Handling

Store lyophilized tirzepatide at -20°C for long-term stability. Reconstituted solution should be stored at 2-8°C and used within 28 days. Avoid repeated freeze-thaw cycles. Use our Reconstitution Calculator for accurate preparation.

Shipping from Canada

All tirzepatide orders ship same-day from our Canadian facility with temperature-controlled packaging. Free shipping on orders over $200 CAD.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

Related Research

• Tirzepatide (Dual GIP/GLP-1) Research Overview
• Semaglutide GLP-1 Receptor Agonist Research
• Retatrutide Triple Agonist Research
• GLP-1 & Incretin Pathway Peptides

For peer-reviewed research on this topic, visit PubMed.

COA Download: View Full COA (PDF) View Full COA (PDF)
Report: DBAV-TIRZ-10-052926